|
1
|
Black CN, Bot M, Scheffer PG, Cuijpers P
and Penninx BW: Is depression associated with increased oxidative
stress? A systematic review and meta-analysis.
Psychoneuro-endocrinology. 51:164–175. 2015. View Article : Google Scholar
|
|
2
|
National Center for Chronic Disease
Prevention and Health Promotion (US) Office on Smoking and Health:
The Health Consequences of Smoking—50 Years of Progress: A Report
of the Surgeon General. Centers for Disease Control and Prevention
(US); Atlanta, GA: 2014
|
|
3
|
Thomas PA, Berbis J, Baste JM, Le
Pimpec-Barthes F, Tronc F, Falcoz PE, Dahan M and Loundou A;
EPITHOR group, : Pneumonectomy for lung cancer: Contemporary
national early morbidity and mortality outcomes. J Thorac
Cardiovasc Surg. 149:73–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W,
Liu Z and Huang JA: MicroRNA-205 targets SMAD4 in non-small cell
lung cancer and promotes lung cancer cell growth in vitro and in
vivo. Oncotarget. 8:30817–30829. 2017.PubMed/NCBI
|
|
5
|
Girard N, Corral J, Cortinovis D and
Heigener DF: Second-line treatment selection in patients with
non-small-cell lung cancer of adenocarcinoma histology: Findings
from a European survey of treating physicians. Clin Lung Cancer.
18:e89–e97. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meaney CL, Zingone A, Brown D, Yu Y, Cao L
and Ryan BM: Identification of serum inflammatory markers as
classifiers of lung cancer mortality for stage I adenocarcinoma.
Oncotarget. 8:40946–40957. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wagland R, Brindle L, Ewings S, James E,
Moore M, Rivas C, Esqueda AI and Corner J: Promoting help-seeking
in response to symptoms amongst primary care patients at high risk
of lung cancer: A mixed method study. PLoS One. 11:e01656772016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sha F, Zhuang S, Zhou L, Zhang L, Yang Y,
Zhang S, Jiang Y, Qiu G, Chen C, Zheng J, et al: Biomarkers for
cancer-related fatigue and adverse reactions to chemotherapy in
lung cancer patients. Mol Clin Oncol. 3:163–166. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yao S, Zhi X, Wang R, Qian K, Hu M and
Zhang Y: Retrospective study of adjuvant icotinib in postoperative
lung cancer patients harboring epidermal growth factor receptor
mutations. Thorac Cancer. 7:543–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen YT, Feng B and Chen LB: Update of
research on drug resistance in small cell lung cancer chemotherapy.
Asian Pac J Cancer Prev. 13:3577–3581. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liew SC: Folic acid and diseases -
supplement it or not? Rev Assoc Med Bras 1992. 62:90–100. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li B, Li MY, Sun LL, Wang J, Zheng YQ and
Hao J: Impact of anticancer drugs price cut on physician's
prescription choices on first-line chemotherapy regimens and health
expenditure for advanced non-small cell lung cancer in China. J
Thorac Dis. 8:2832–2842. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim
HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, et al
AURA3 Investigators, : Osimertinib or platinum-pemetrexed in EGFR
T790M-positive lung cancer. N Engl J Med. 376:629–640. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
de Kock I, Mirhosseini M, Lau F, Thai V,
Downing M, Quan H, Lesperance M and Yang J: Conversion of Karnofsky
Performance Status (KPS) and Eastern Cooperative Oncology Group
Performance Status (ECOG) to Palliative Performance Scale (PPS),
and the interchangeability of PPS and KPS in prognostic tools. J
Palliat Care. 29:163–169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guenther LM, Rowe RG, Acharya PT, Swenson
DW, Meyer SC, Clinton CM, Guo D, Sridharan M, London WB, Grier HE,
et al: Response Evaluation Criteria in Solid Tumors (RECIST)
following neoadjuvant chemotherapy in osteosarcoma. Pediatr Blood
Cancer. 65:652018. View Article : Google Scholar
|
|
17
|
Luo Y, Li J, Wang Y, Hao X and Qu F:
Nimotuzumab combined with chemotherapy as second- or later-line in
the treatment of advanced lung squamous cell carcinoma. Zhongguo
Fei Ai Za Zhi. 19:665–669. 2016.(In Chinese). PubMed/NCBI
|
|
18
|
Fritz I and Olsson H: Lung cancer in young
women in southern Sweden: A descriptive study. Clin Respir J.
12:1565–1571. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Murphy RA, Mourtzakis M, Chu QS, Baracos
VE, Reiman T and Mazurak VC: Supplementation with fish oil
increases first-line chemotherapy efficacy in patients with
advanced nonsmall cell lung cancer. Cancer. 117:3774–3780. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanesvaran R, Roy Chowdhury A and Krishna
L: Practice pearls in the management of lung cancer in the elderly.
J Geriatr Oncol. 7:362–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou L, He J, Xiong W, Liu Y, Xiang J, Yu
Q, Liang M, Zhou X, Ding Z, Huang M, et al: Impact of whole brain
radiation therapy on CSF penetration ability of Icotinib in
EGFR-mutated non-small cell lung cancer patients with brain
metastases: Results of phase I dose-escalation study. Lung Cancer.
96:93–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Song Z, Su H and Zhang Y: Patients with
ROS1 rearrangement-positive non-small-cell lung cancer benefit from
pemetrexed-based chemotherapy. Cancer Med. 5:2688–2693. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Scheinpflug K, Menzel C, Koch A, Kahl C
and Achenbach HJ: Toxic epidermal necrolysis related to cisplatin
and pemetrexed for metastatic non-small cell lung cancer.
Onkologie. 35:600–603. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ping W, Gao Y, Fan X, Li W, Deng Y and Fu
X: MiR-181a contributes gefitinib resistance in non-small cell lung
cancer cells by targeting GAS7. Biochem Biophys Res Commun.
495:2482–2489. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ding T, Zhou F, Chen X, Zhang S, Liu Y,
Sun H, Ren S, Li X, Zhao C, Wang H, et al: Continuation of
gefitinib plus chemotherapy prolongs progression-free survival in
advanced non-small cell lung cancer patients who get acquired
resistance to gefitinib without T790M mutations. J Thorac Dis.
9:2923–2934. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Y, Zhang Y, Feng G, Niu Q, Xu S, Yan
Y, Li S and Jing M: Comparison of effectiveness and adverse effects
of gefitinib, erlotinib and icotinib among patients with non-small
cell lung cancer: A network meta-analysis. Exp Ther Med.
14:4017–4032. 2017.PubMed/NCBI
|
|
28
|
Lee JK, Hahn S, Kim DW, Suh KJ, Keam B,
Kim TM, Lee SH and Heo DS: Epidermal growth factor receptor
tyrosine kinase inhibitors vs conventional chemotherapy in
non-small cell lung cancer harboring wild-type epidermal growth
factor receptor: A meta-analysis. JAMA. 311:1430–1437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fennell DA, Gaudino G, O'Byrne KJ, Mutti L
and van Meerbeeck J: Advances in the systemic therapy of malignant
pleural mesothelioma. Nat Clin Pract Oncol. 5:136–147. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen M, Cao H, Ji Y, Mao Y, Shen S and Li
X: Association between the ALK Gene Status and the efficacy of
first-line pemetrexed chemotherapy in patients with advanced lung
adenocarcinoma. Zhongguo Fei Ai Za Zhi. 20:732–736. 2017.(In
Chinese). PubMed/NCBI
|
|
31
|
Shi Y, Zhang L, Liu X, Zhou C, Zhang L,
Zhang S, Wang D, Li Q, Qin S, Hu C, et al: Icotinib versus
gefitinib in previously treated advanced non-small-cell lung cancer
(ICOGEN): A randomised, double-blind phase 3 non-inferiority trial.
Lancet Oncol. 14:953–961. 2013. View Article : Google Scholar : PubMed/NCBI
|
